Treatment Action Group (TAG) submitted comments to the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) in response to a public request for information (RFI) to inform NIAID's Tuberculosis Strategic Plan on supporting TB research and development (R&D).
Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Read Mark and Demetre's response to The New York Times June 26 opinion piece, "The End of Safe Gay Sex?"
Letter to Dr. Tedros Adhanom Ghebreyesus, Director-General, WHO, and Dr. Tereza Kasaeva, Global TB Program Director.
A group of 97 International, U.S., Canadian, and Mexican health organizations sent this letter to representatives of those countries, asking them to ensure that any North American Free Trade Agreement (NAFTA) renegotiations don’t undermine access to affordable medicines.
Gilead Sciences is limiting access to Truvada as a component of nonoccupational postexposure prophylaxis (nPEP) through its patient assistance program to once in a lifetime, with hardship review criteria and processes for subsequent prescriptions that have not been clearly articulated and are likely a considerable barrier to nPEP by uninsured and underinsured U.S. residents.
TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
TAG’s comments on the Divisions of AIDS (DAIDS) in advance of the recompetition of its clinical trials networks.
A review of comments submitted by TAG to the Office of the United Nations High Commissioner for Human Rights, in response to a request for submissions from interested organizations and stakeholders for the preparation of its report on Sustainable Development Goals and Health.
TAG’s comments to the Health Subcommittee of the U.S. House of Representatives Energy and Commerce Committee, in association with its hearing, “Examining Patient Access to Investigational Drugs,” and the deliberations of H.R. 1020, the Compassionate Freedom of Choice Act of 2017, and S. 204, the Right to Try Act of 2017.